The question everyone asks before their first injection is "when will I feel something?" And the question everyone asks at week three — when the scales haven't moved much — is "is this actually working?" Both questions deserve better answers than the generic reassurance most people receive from their provider.

This guide takes you through the experience of Mounjaro or Wegovy treatment at the level of detail most people actually want: day one, day three, day five, day seven, and then week by week through the critical first eight weeks when most patients either find their rhythm or lose confidence and stop. It covers the pharmacology — what the drug is actually doing in your body at each point — alongside what most patients actually notice. Both drugs are covered, with the meaningful differences between them highlighted where they matter.

One thing to understand before you start: both Mounjaro and Wegovy are weekly injections. The starter doses (2.5mg for Mounjaro, 0.25mg for Wegovy) are not therapeutic doses for weight loss. They're initiation doses designed to minimise side effects while your body adjusts. If you feel little in week one, that's by design. The weight loss and appetite suppression you're hoping for builds over weeks, not days.

Understanding the day-by-day experience starts with understanding how tirzepatide (Mounjaro) and semaglutide (Wegovy) move through your body after each injection.

Both drugs are injected subcutaneously — into fat tissue just under the skin — and absorbed gradually into the bloodstream. Neither acts immediately. After a Mounjaro injection, tirzepatide reaches its peak blood concentration around 24 to 48 hours later. Days one and two are when you're most likely to feel the strongest effects. Concentration remains high and relatively stable through days three to five, then begins to decline. By day seven, tirzepatide levels are lower — which is why some patients notice a slight increase in hunger in the days before their next injection, particularly in the early weeks before steady-state blood levels are established.

Wegovy (semaglutide) follows a slightly different curve. Semaglutide peaks approximately 24 to 36 hours after injection and has a half-life of around seven days — meaning it takes longer to clear the system than tirzepatide, which has a half-life of approximately five days. Wegovy's blood levels are therefore somewhat more stable throughout the week, with less pronounced day-to-day variation than Mounjaro, particularly at maintenance doses.

What this means practically: your experience won't be the same every day. The drug's effects on appetite, nausea, and energy follow a weekly cycle that becomes more predictable over time. Learning your own pattern — which days feel strongest, which days feel closer to normal — is one of the most useful things you can do in the first month.

The pen has been in the fridge. Allow it to come to room temperature for 30 minutes before injecting — cold medication increases discomfort. Choose your injection site: abdomen (at least 5cm from the navel), outer thigh, or upper arm. Wash your hands. Decide which day of the week will be your weekly injection day and write it in your diary.

One underrated preparation: eat a light, protein-rich meal or snack before your first injection rather than injecting on an empty stomach or after a heavy meal. A large meal slows gastric emptying even without medication — the combination of a heavy meal and your first dose can intensify nausea significantly.

Calibrate your expectations. You're unlikely to feel dramatically different after your first injection. You're unlikely to lose weight in week one. The first injection is about beginning the process, not immediate transformation. Patients who approach week one with curiosity rather than urgency tend to have a far better early experience than those expecting dramatic change from day one.

The injection itself takes seconds. Most people describe it as a small pinch, or nothing at all. The fine needle and small volume mean it's almost universally less uncomfortable than anticipated. Inject, hold for five seconds, remove. Dispose of the pen in your sharps bin.

In the hours immediately after injection, tirzepatide begins binding to GLP-1 and GIP receptors but blood concentrations are still rising. Semaglutide does the same with GLP-1 receptors alone. Most people feel very little in the first six to eight hours.

What some people notice on day one: a subtle sense of reduced appetite at the meal following the injection — satisfied a little sooner than usual. Mild injection site redness or tenderness, which is normal and will resolve within a few hours to a day. Or nothing at all, which is also completely normal on the starter dose.

What you should do: eat your usual meals slowly, and stop the moment you feel comfortably full. Have plain, easy-to-digest options available for the evening in case nausea arrives later. Drink water consistently throughout the day. Don't weigh yourself.

For Mounjaro patients, this is typically when the drug's effects are most pronounced. Blood concentration of tirzepatide has reached or is near its peak. For Wegovy patients, days two to three are similarly the peak phase, though the curve is slightly more gradual.

What most people notice: a more obvious and sustained reduction in appetite — meals feel satisfying with noticeably smaller portions. The beginning of what many patients call "food noise" reduction — the mental chatter about food, the compulsive thinking about the next meal, starts to quiet. Nausea, if it's going to occur, typically arrives in this window. For most patients on a starter dose it's mild, a background queasiness rather than acute sickness. Some experience loose stools or diarrhoea, as GLP-1 receptor activation throughout the gut alters how the intestines process food and fluid. Fatigue is also common, usually a combination of reduced calorie intake and the metabolic adjustment beginning.

Practical tips for days two to three: eat small, plain meals and avoid fatty, fried, or heavily spiced food, which worsens nausea on a stomach that's already emptying slowly. Don't force yourself to finish a plate. Cold foods — Greek yoghurt, protein shake, crackers — are better tolerated than hot dishes if nausea is significant. Sip water consistently in small amounts rather than large glasses. Ginger tea can help with mild nausea.

Blood concentration remains high but has begun its gradual post-peak decline. For most patients, days four and five represent the beginning of a settling pattern — the acute peak effects are past, but the drug is still very much active.

What most people notice: nausea, if present, often begins to ease. Appetite suppression remains strong — this is a good time to test what eating to true hunger actually feels like for you. Energy levels may begin to recover as the body adapts. Some patients notice more stable blood sugar and the absence of the afternoon energy dip that many people with obesity experience. Constipation may begin to become noticeable if it's going to occur — increase fluid intake and dietary fibre proactively.

Many patients find day four or five the first day that feels genuinely positive rather than just uncomfortable adjustment. The nausea has often eased, the appetite reduction feels manageable rather than alarming, and the experience of eating less without being miserable starts to land.

For Mounjaro patients in particular, day seven can feel noticeably different from days two to five. Tirzepatide's shorter half-life means blood levels are meaningfully lower by day seven than they were at peak. For many patients — particularly in the early weeks before steady-state accumulation is established — this translates into a modest return of hunger and food thoughts that felt quieter earlier in the week.

This is entirely normal and not a sign the drug is wearing off. Once you've been on the medication for several weeks and blood levels have accumulated to a steady state, the day seven dip becomes less pronounced for most patients.

What most people notice: slightly more hunger or food thoughts than days two to five, particularly in the first two to four weeks. Energy levels often feel best on day six or seven — the nausea of the early days is gone and hunger hasn't yet returned fully. A sense of readiness for the next injection.

Inject at the same time as your previous injection, on the same day of the week. Consistency matters — tirzepatide and semaglutide maintain more stable blood levels when injected on schedule. Missing your injection day by one or two days is usually manageable, but try not to make it a habit.

Week one is almost universally the most surprising week — either because you felt more than expected, or because you felt less. Clinical data on weight loss in week one: minimal. Average weight change is zero to 1kg, and most of this is water loss from reduced food intake and early glycogen depletion rather than true fat loss. Don't judge the medication by week one weight loss.

What the body is doing: establishing the pharmacokinetic baseline. Drug levels are rising to early steady state. The gut is beginning to adapt to sustained GLP-1 (and GIP, for Mounjaro) receptor signalling. The brain's appetite circuits are beginning to respond.

What matters this week: completing the first injection, getting through the day two nausea window, establishing your injection day routine, and beginning to practise eating to satiety signals rather than habit. Not weight loss. Not dramatic transformation. Foundations.

This is typically the week where the experience becomes more defined. Blood levels are approaching a more stable steady state, and the pattern of days one to seven becomes clearer and more predictable.

What most people notice: food noise reduction is often more striking this week than the physical fullness — many patients describe the mental change as more notable than the scale. Meals feel more manageable. Nausea may still be present around days two to three but is often less intense than week one as the gut continues adapting. A few patients notice very little — still normal at the starter dose. The therapeutic dose builds from week five onwards.

Weight: approximately 0.5 to 1.5kg from baseline. Still largely water and glycogen reduction. True fat mobilisation is beginning but isn't yet the dominant source of the small weight change.

Practical focus this week: protein intake. Many people in week two reduce their eating but don't manage the protein transition well — total food falls but so does protein, which accelerates fatigue and muscle loss risk. Prioritise protein at every meal even as portions shrink.

Week three is frequently the hardest emotional week of the entire treatment period. The novelty of starting has worn off, the dramatic early changes like food noise reduction have settled into a new normal, the scale has moved only modestly, and side effects may still be present. Many patients question whether the medication is working.

The clinical reality: week three is exactly where it should be. You're still on the starter dose. The therapeutic weight loss dose begins to activate from week five. Week three is not a failure — it's a transitional week between initiation and early therapeutic effect.

What most people notice: nausea peaks for some patients this week, though for many it has already improved since week one. A possible mid-week energy dip as the body adjusts its metabolic expectations around a lower calorie intake. The "I'm not sure this is working" doubt — very common and not a reliable indicator of anything. Some patients notice their first meaningful reduction in evening snacking, which can be a significant shift that the scale doesn't immediately reflect.

Weight: approximately 1 to 3% from baseline. Still within the adjustment range rather than therapeutic weight loss. Patience is both necessary and clinically correct at this stage.

By week four, most patients have found something approaching a routine. The injection day pattern — stronger effects on days two to three, settling days four to five, mild hunger return on day seven — is familiar. Side effects for most patients have improved significantly from their week two to three peak. Eating less feels less effortful and more automatic.

This is the last week at the starter dose for both Mounjaro and Wegovy. At week five, the dose increases — Mounjaro to 5mg, Wegovy to 0.5mg. This will cause a brief return of side effects for many patients as the body adjusts.

What most people notice: a genuine settling — the new relationship with food feels more sustainable than it did in week one. Hair loss may begin to be noticeable for the small minority who experience it — this is telogen effluvium from rapid calorie restriction, not a direct drug effect. Energy often improves compared to weeks two to three. The scale is moving more consistently, even if slowly.

Weight: approximately 2 to 4% from baseline. For a starting weight of 90kg, that's 1.8 to 3.6kg. For 120kg, 2.4 to 4.8kg. This is real progress, even if it feels modest.

The first dose increase is a significant moment — and for many patients, a welcome one. It's also when many experience a brief recurrence of side effects. This is normal, expected, and nearly always temporary.

What to expect: a brief return of nausea around days two to three of the new dose — usually less intense than week one but noticeable. Stronger appetite suppression than the starter dose — many patients find this is where the drug starts feeling genuinely powerful. For Mounjaro patients, the dual GLP-1/GIP mechanism becomes more pronounced at higher doses, which is why tirzepatide's weight loss advantage over semaglutide grows more marked as doses increase. Possible increase in constipation if it was already occurring.

Weight: the dose increase often produces accelerated weight loss over weeks five to eight. Many patients lose more in the month of their first dose increase than they did in the first four weeks combined.

By weeks six and seven, most patients have adapted to the higher dose. Side effects have settled again and the full appetite suppression effect of this dose level is established. This is often described as the week when the medication "clicks" — when patients first truly understand what the drug is doing, because the appetite suppression is strong enough to be unmistakable but they've adapted enough that it doesn't feel alarming.

What most people notice: the weekly cycle is now well understood and manageable — patients know which days to plan light meals and which days feel more normal. Weight loss is measurably accelerating compared to weeks one to four. Energy levels are often better than at the start. Some patients begin to feel genuinely motivated — the results are becoming visible to themselves and others. If you haven't started resistance training yet, this is a good week to begin.

Weight: approximately 5 to 7% from baseline. At 90kg starting weight, that's 4.5 to 6.3kg. At 120kg, 6 to 8.4kg. This is clinically meaningful weight loss — blood pressure, blood sugar, and inflammatory markers are improving measurably even at this relatively early stage.

Week eight brings the second dose increase and another brief adjustment period. By this point, most patients have been through one dose increase already and know what to expect — a few days of heightened nausea and potentially looser stools, followed by adaptation and improved appetite suppression.

For Mounjaro patients, the transition to 7.5mg is particularly significant. The dose-response relationship with tirzepatide is pronounced, and many patients notice a clear step-change in appetite suppression at this level. Weeks eight to sixteen are typically the fastest period of weight loss in the entire treatment course.

What most people notice: side effects return briefly on days two to three of the new dose — by now a familiar pattern. For many patients, week eight is the first time the drug feels like it's truly doing what it's supposed to do, because the appetite suppression is now substantial. Cravings for high-fat and high-sugar processed foods may have reduced markedly as GLP-1 receptor activation in the brain's reward circuits becomes increasingly pronounced.

Weight: approximately 5 to 9% from baseline. Those who have also made dietary and exercise changes will often be at the higher end of this range.

Weight loss percentages are averages based on clinical trial data — individual results vary depending on starting weight, dose tolerated, dietary adherence, and exercise. Some patients will be above these averages; some below. Neither outcome necessarily reflects whether the drug is working correctly.

For most of the day-by-day experience described above, Mounjaro and Wegovy follow similar patterns. There are, however, meaningful differences worth knowing.

Mounjaro's shorter half-life means the peak effects and potential nausea are somewhat more concentrated in days two to three compared to Wegovy's slightly more gradual curve. Mounjaro patients may experience a more pronounced but shorter nausea window; Wegovy patients a more extended but lower-intensity initial adjustment.

The day seven hunger dip is more commonly reported with Mounjaro than Wegovy, because tirzepatide's five-day half-life produces a more pronounced trough before the next weekly injection than semaglutide's seven-day half-life.

The week three "nothing is happening" doubt is more common among Wegovy patients, whose starter dose of 0.25mg is even further below therapeutic level than Mounjaro's 2.5mg. The clearer therapeutic effects of Wegovy begin from week nine (the 1mg dose) onward.

Mounjaro's dose increases occur every four weeks in 2.5mg steps. The adjustment period after each Mounjaro dose increase is generally reported as more noticeable but shorter than Wegovy's.

For most patients, Mounjaro's appetite suppression is more complete at maximum doses than Wegovy's — consistent with the SURMOUNT-5 trial showing 20.2% versus 13.7% weight loss. Patients switching from Wegovy to Mounjaro often remark on the more pronounced food noise reduction.

Contact your prescriber or seek urgent care if you experience any of the following:

Severe, persistent upper abdominal pain that radiates to the back — this is a possible pancreatitis warning sign. Stop the medication and seek urgent care immediately. Vomiting that prevents you keeping fluids down for more than 24 hours. No change in appetite or experience whatsoever after three consecutive injections — discuss dose escalation or drug suitability. Significant mood changes, depression, or thoughts of self-harm. Severe dizziness, particularly if you're on blood pressure medication. Injection site reactions that worsen or spread significantly beyond the injection point.

When will I feel the effects of my first Mounjaro or Wegovy injection?
 For Mounjaro, the effects typically become noticeable around 24 to 48 hours after the first injection, when blood concentration reaches its peak. For Wegovy, the timeline is similar, with peak effects 24 to 36 hours post-injection. On the starter dose, the effects may be very subtle — these doses are designed for adjustment, not maximum appetite suppression. Stronger effects emerge as doses increase from week five onwards.

Why do I feel more hungry on day seven before my next injection?
 This is expected and pharmacologically predictable. Tirzepatide has a half-life of approximately five days, meaning blood levels are meaningfully lower by day seven than at the day two peak. Some patients notice a mild return of hunger in the day or two before their next weekly injection, particularly in the first four to six weeks before drug levels have fully